Sigilon Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

Rhea-AI Summary

Sigilon Therapeutics (NASDAQ:SGTX), a biotech firm focused on functional cures for chronic diseases, announced participation in two healthcare investor conferences. CEO Rogerio Vivaldi will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 8:00 AM ET in a live fireside chat. He will also present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET through an on-demand corporate presentation. Webcasts will be available on the company's website.

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in two upcoming healthcare investor conferences.

Presentation Details:

Event: Morgan Stanley 19^th Annual Global Healthcare Conference
Date: Friday, September 10, 2021
Time: 8:00 AM ET
Details: Live Fireside Chat

Event: H.C. Wainwright 23^rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: 7:00 AM ET
Details: On Demand Corporate Presentation

Webcasts of the Morgan Stanley fireside chat and the H.C. Wainwright corporate presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company's website at www.sigilon.com. A replay of each webcast will be available at the same location following the event.

About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor Contact
Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837

Media Contacts
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349

Brandon Hagen
Manager, Communications
Sigilon Therapeutics
brandon.hagen@sigilon.com
617-586-2851

FAQ

When will Sigilon Therapeutics present at the Morgan Stanley conference?

Sigilon Therapeutics will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 8:00 AM ET.

What is the date and time of the H.C. Wainwright conference for Sigilon Therapeutics?

The H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13, 2021, at 7:00 AM ET.

How can I access the webcasts for Sigilon Therapeutics' presentations?

Webcasts for Sigilon Therapeutics' presentations will be accessible under the 'Events and Presentations' section on their website.

What is the focus of Sigilon Therapeutics' research?

Sigilon Therapeutics focuses on developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform.

What kind of therapies does Sigilon Therapeutics develop?

Sigilon Therapeutics develops non-viral engineered cell-based therapies for chronic diseases like hemophilia, lysosomal diseases, and diabetes.